Teva Pharmaceutical Industries Limited (NYSE:TEVA) grew as high as $18.82 on Monday before closing at $18.82. The 3.29 percent rally pushed its market cap to $20.93B. The shares went down as low as $18.31 before recovering. Trading activity significantly improved as the volume at ready counter increased to 8,452,673 shares versus 7,486,380 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 8,361,314 shares. The stock is now 28.99% above against its bear-market low of $14.59 on December 24, 2018. It has retreated -37.94% since it’s 52-week high of $25.96 reached in August. Now the market price is up 0.97% on the year and up 22.05% YTD.

TEVA’s 50 day simple moving average (SMA 50) price is $18.46 and its 200-day simple moving average (SMA 200) price is $21.33. The company’s stock currently has a total float of 1.05B shares. Its weekly volatility is hovering around 3.53% and felt 2.44% volatility in price over a month. On the upside, the share price will test short term resistance at around $18.99. On a downside, the stock is likely to find some support, which begins at $18.48. The failure to get near-term support could push it to $18.14.

Separately, it has been reported that multiple insider activity took place at Teva Pharmaceutical Industries Limited (TEVA). Executive VP, Global R&D Fridriksdottir Hafrun sold 1,643 shares for $11,826 in transaction occurred on 2019/01/02. After making this transaction, the Executive VP, Global R&D owns a direct stake of 25,795 shares, worth $222,565, as per the last closing price. On 2018/11/30 Fridriksdottir Hafrun, Executive VP, Global R&D at TEVA, dumped 933 shares at an average price of $21.76 per share. The selling total is valued at $166,162.

EVP, CFO, Mcclellan Michael James had divested 346 shares for $11,644 through a trade on 2018/11/05. Following this activity, the insider holds 7,865 shares worth $219,140 as of recent close. Wall Street’s most bullish Teva Pharmaceutical Industries Limited (NYSE:TEVA) analysts are predicting the share price to blow past $30 per share during the next 12 months. The current median share price forecast by them is $24, suggesting that the stock could increase 27.52% in that time frame. The average price target of $22.12 calls for a nearly 17.53% increase in the stock price.

It had seen a positive analyst call from UBS, which upgraded the stock from Neutral to Buy on January 23. Analysts at Piper Jaffray, shed their negative views on January 23 by lifting it fromUnderweight to Neutral. The stock won favor of BofA/Merrill analysts who expressed their confidence in it using an upgrade from Underperform to Buy on January 03.

Moreover, it trades for 6.67 times the next 12 months of expected earnings. Also, it is trading at rather expensive levels at just over 1.38x price/book and 1.06x price/sales. Compared to others, Teva Pharmaceutical Industries Limited is in a different league with regards to profitability, having net margins of -56%. To put some perspective around this, the industry’s average net margin is 5.98%. TEVA’s ROE is -78%, which is also considerably worse than the industry’s ROE of 14.33%. It’s also not liquid in the near term, with a current ratio of 0.9. The stock has a debt/capital of 2.12.

Shares of Teva Pharmaceutical Industries Limited (TEVA) have dropped -8.8% since the company’s last earnings report. Over the past 12 fiscal quarters, Teva Pharmaceutical Industries Limited (NYSE:TEVA) has topped consensus earnings estimates in 7 quarters (58%), missed earnings in 2 quarters (16%), whereas at 3 occasion EPS met analyst expectations. TEVA last reported earnings on November 01, 2018 when it released Sep-18 results that exceeded expectations. The company raked in $0.68 per share, -97.37% change on the same period last year. That was better than consensus for $0.54. Revenue for the recent quarter stood at $4.53 billion, down -19% on last year and below the $4.53 billion predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $4.46 billion to $4.71 billion, which should be compared with $4.63 billion generated last year. EPS is seen in a range of $0.63 to $0.74, against the $0.88 reported a year ago.